Loading…
Clinitech Laboratory (BSE 544220)₹30.000.00%Healthcare Service Provider
In the Mar 2026 quarter (consolidated), Clinitech Laboratory reported sales of ₹4.40 Cr, up 6.0% from Mar 2025, and net profit of ₹0.13 Cr, down 27.8% year on year. For the year to Mar 2026, sales were ₹9.47 Cr and net profit ₹0.43 Cr.
Company filings, consolidated accounts; latest reported quarter Mar 2026
| Mar 2025 | Sep 2025 | Mar 2026 | |
|---|---|---|---|
| Sales | 4.15 | 5.07 | 4.40 |
| Expenses | 3.89 | 4.55 | 3.97 |
| Operating Profit | 0.27 | 0.53 | 0.44 |
| OPM % | 6.7% | 10.6% | 10.2% |
| Other Income | 0.18 | 0.12 | 0.09 |
| Interest | 0.01 | 0.04 | 0.01 |
| Depreciation | 0.15 | 0.26 | 0.27 |
| Profit before tax | 0.28 | 0.34 | 0.26 |
| Tax % | 41.4% | 14.3% | 52.0% |
| Net Profit | 0.18 | 0.31 | 0.13 |
| EPS (Rs) | 0.75 | 1.32 | 0.52 |
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Sales | 8.21 | 9.47 |
| Expenses | 7.41 | 8.52 |
| Operating Profit | 0.82 | 0.98 |
| OPM % | 10.1% | 10.4% |
| Other Income | 0.24 | 0.20 |
| Interest | 0.05 | 0.06 |
| Depreciation | 0.46 | 0.52 |
| Profit before tax | 0.54 | 0.61 |
| Tax % | 29.1% | 30.0% |
| Net Profit | 0.40 | 0.43 |
| EPS (Rs) | 1.72 | 1.83 |
| Dividend payout % | 0.0% | 0.0% |
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Equity Capital | 2.27 | 2.27 |
| Reserves | 6.54 | 6.96 |
| Borrowings | 0.00 | 0.55 |
| Other Liabilities | 2.00 | 1.38 |
| Total Liabilities | 10.81 | 11.16 |
| Fixed Assets | 3.12 | 3.16 |
| CWIP | 0.00 | 0.27 |
| Investments | 0.06 | 0.06 |
| Other Assets | 7.63 | 7.67 |
| Inventories | 0.54 | 0.74 |
| Trade receivables | 1.53 | 1.84 |
| Cash & equivalents | 3.06 | 2.10 |
| Total Assets | 10.81 | 11.16 |
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Cash from operating activity | −0.87 | −0.78 |
| Cash from investing activity | −0.74 | −0.69 |
| Cash from financing activity | 3.97 | 0.50 |
| Net cash flow | 2.38 | −0.97 |
| Capex | 1.17 | 0.84 |
| Free cash flow | −1.74 | −1.61 |
| CFO / OP % | −87.0% | −59.1% |
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Debtor days | 67 | 70 |
| Inventory days | 123 | 117 |
| Days payable | 179 | 79 |
| Cash conversion cycle | 13 | 111 |
| Working capital days | 115 | 159 |
| ROCE % | — | 7.2% |
For the Mar 2026 quarter, Clinitech Laboratory reported sales of ₹4.40 Cr, up 6.0% year on year and net profit of ₹0.13 Cr, down 27.8% year on year. The operating margin was 10.2%.
Clinitech Laboratory's sales for the year to Mar 2026 were ₹9.47 Cr.
Net profit for the year to Mar 2026 was ₹0.43 Cr. Earnings per share over the same trailing period were ₹1.83.
Clinitech Laboratory reported borrowings of ₹0.55 Cr at Mar 2026, against cash and equivalents of ₹2.10 Cr.
Cash from operations was −₹0.78 Cr in the year to Mar 2026; after capital spending, free cash flow was −₹1.61 Cr.